IPO registrations (S-1, F-1) · Registrants
MADRIGAL PHARMACEUTICALS, INC.
- SEC CIK
- 1157601 · filings on EDGAR ↗
- Name on the registration
- SYNTA PHARMACEUTICALS CORP
- Former names
- SYNTA PHARMACEUTICALS CORP (2002–2016)
- Registration
- Form S-1, first filed 2005-01-18, last 2007-02-05; 2 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2007-02-07; declared effective 2007-02-05; withdrawal requested 2005-06-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, West Conshohocken, PA
- Ticker
- MDGL (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- MADRIGAL PHARMACEUTICALS, INC. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2007-02-05)
- Final price
- $10.00 per share, below the range (424B4 filed 2007-02-07, an initial public offering)
- Shares sold
- 5,000,000
- Gross proceeds
- $50,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SNTA
- Lead underwriters
- Bear Stearns (2,000,000 shares)
- Syndicate
- Lehman Brothers (2,000,000); Lazard (750,000); Montgomery & Co., LLC (250,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Madrigal Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: Madrigal Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: Madrigal Pharmaceuticals, Inc. Fuzzy (name and state)
- Business registration: MADRIGAL PHARMACEUTICALS, INC Fuzzy (name and state)
- Business registration: MADRIGAL PHARMACEUTICALS, INC Fuzzy (name and state)
- Business registration: MADRIGAL PHARMACEUTICALS, INC Fuzzy (name and state)
- Business registration: MADRIGAL PHARMACEUTICALS, INC Fuzzy (name and state)
- Business registration: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- Federal award recipient: MADRIGAL PHARMACEUTICALS, INC Fuzzy (name and state)
- Form D issuer: MADRIGAL PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
- Lobbying client: MADRIGAL PHARMACEUTICALS Fuzzy (name and state)
- Lobbying client: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying client: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying client: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying client: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying registrant: MADRIGAL PHARMACEUTICALS, INC. Fuzzy (name and state)
- SEC filer: MADRIGAL PHARMACEUTICALS, INC. EXACT (CIK (EXACT))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2005-01-18 | S-1 | S-1 (registration) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-001033 ↗ |
| 2005-02-23 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-004481 ↗ |
| 2005-03-17 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-006934 ↗ |
| 2005-04-22 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-010966 ↗ |
| 2005-04-29 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-012454 ↗ |
| 2005-06-13 | RW | RW (withdrawal request) | SYNTA PHARMACEUTICALS CORP | 0001047469-05-017134 ↗ |
| 2006-11-22 | S-1 | S-1 (registration) | SYNTA PHARMACEUTICALS CORP | 0001047469-06-014434 ↗ |
| 2006-12-01 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-06-014679 ↗ |
| 2007-01-04 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-07-000036 ↗ |
| 2007-01-23 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-07-000315 ↗ |
| 2007-02-05 | S-1/A | S-1/A (amendment) | SYNTA PHARMACEUTICALS CORP | 0001047469-07-000597 ↗ |
| 2007-02-05 | EFFECT | EFFECT (declared effective) | SYNTA PHARMACEUTICALS CORP | 9999999995-07-000448 ↗ |
| 2007-02-06 | EFFECT | EFFECT (declared effective) | SYNTA PHARMACEUTICALS CORP | 9999999995-07-000475 ↗ |
| 2007-02-07 | 424B4 | 424B4 (final prospectus) | SYNTA PHARMACEUTICALS CORP | 0001047469-07-000713 ↗ |
| 2008-08-28 | EFFECT | EFFECT (declared effective) | SYNTA PHARMACEUTICALS CORP | 9999999995-08-002664 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2007-02-05 | S-1/A | registration statement | $14.00–$16.00 | $15.00 | 6,000,000 | $90,000,000 | Nasdaq SNTA | 4 | primary document; range, price sentence, shares headline, proceeds computed, cover names 4 | document ↗ |
| 2007-02-07 | 424B4 | final prospectus | $10.00 | 5,000,000 | $50,000,000 | Nasdaq SNTA | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bahcall Safi R | Director,Officer | President and CEO | 26 | 2007–2014 | |
| Barsoum James G | Officer | Sr. VP, Research | 4 | 2007–2009 | |
| CAXTON CORP | TenPercentOwner | 2 | 2007 | ||
| Chadwick Jeremy G | Officer | Sr. VP, Pgm Mgmt and Clin Ops; Sr. VP, Program Mgmt and Ops | 7 | 2007–2010 | |
| Chen Lan Bo | Director; Director,TenPercentOwner | 9 | 2007–2013 | ||
| Chen Lin Huey | TenPercentOwner | 6 | 2007–2010 | ||
| CxSynta LLC | TenPercentOwner | 2 | 2007 | ||
| Ehrlich Keith S | Officer | VP, Fin. and Admin., CFO | 13 | 2007–2014 | |
| Folkman Judah | Director | 2 | 2007 | ||
| Gollust Keith R | Director | 37 | 2007–2022 | ||
| Jacobson Eric W | Officer | Sr. VP, Research and CMO | 5 | 2007–2009 | |
| Kovner Bruce | Director,TenPercentOwner | 52 | 2007–2015 | ||
| Koya Keizo | Officer | Sr. VP, Drug Development | 11 | 2007–2012 | |
| REARDON WILLIAM S | Director | 11 | 2007–2015 | ||
| Rieder Wendy E | Officer | Former SVP, Gen. Counsel; SVP, Gen. Counsel; VP, IP and Legal, Gen. Counsel | 17 | 2007–2016 | |
| Williams Martin D | Officer | Sr. VP, Business Dev., CBO | 5 | 2007–2008 | |
| WILSON ROBERT N | Director | 17 | 2007–2015 | ||
| BAILEY MICHAEL P | Officer | Sr. VP, Chief Comm. Officer | 5 | 2008–2010 | |
| Vukovic Vojo | Officer | SVP, Chief Medical Officer | 14 | 2009–2015 | |
| KUFE DONALD W | Director | 9 | 2010–2015 | ||
| Singh Amar | Officer | Sr. VP, Business & Comm. Dvp.; Sr. VP, Chief Business Officer | 7 | 2010–2014 | |
| Ramachandra Sumant | Officer | President, R&D | 2 | 2013 | |
| Bernitz Steven B | Officer | SVP, Corporate Development | 2 | 2013 | |
| McMahon Arthur | Officer | SVP, Human Resources; SVP, People Operations | 3 | 2014–2015 | |
| FRIEDMAN PAUL A | Director; Director,Officer | Chief Executive Officer | 29 | 2014–2026 | |
| Whitaker Anne Clem | Director,Officer | President and CEO | 3 | 2014–2015 | |
| Schneebaum Marc R | Officer | Chief Financial Officer; SVP and CFO | 12 | 2014–2021 | |
| Schor Chen | Director,Officer; Officer | Executive VP and COO; Former President and CEO; President and CEO | 6 | 2014–2016 | |
| Morenstein Scott D | Director | 3 | 2015–2016 | ||
| BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP | Director,TenPercentOwner; TenPercentOwner | 7 | 2016–2021 | ||
| Bay City Capital Fund IV, L.P. | Director,TenPercentOwner; TenPercentOwner | 7 | 2016–2021 | ||
| BAY CITY CAPITAL LLC | Director,TenPercentOwner; TenPercentOwner | 8 | 2016–2021 | ||
| Bay City Capital Management IV LLC | Director,TenPercentOwner; TenPercentOwner | 7 | 2016–2021 | ||
| CRAVES FRED B | Director; Director,TenPercentOwner | 29 | 2016–2025 | ||
| Taub Rebecca | Director; Director,Officer; Director,Officer,TenPercentOwner | Chief Medical Officer, EVP R&D; President of R&D; Pres., R&D, and CMO; See Remarks | 29 | 2016–2026 | |
| BATE KENNETH | Director | 16 | 2016–2025 | ||
| MILLIGAN DAVID V | Director | 13 | 2016–2022 | ||
| Levy Richard S | Director | 24 | 2016–2026 | ||
| Lynch Brian Joseph | Officer | See Remarks; SVP and General Councel; SVP and General Counsel | 13 | 2019–2024 | |
| Daly James M | Director | 11 | 2019–2026 | ||
| Sukhija Remy | Officer | Chief Commercial Officer; SVP and Chief Comm'l Officer | 5 | 2020–2023 | |
| Howarth Alex G. | Officer | Chief Financial Officer | 7 | 2021–2024 | |
| Waltermire Robert E. | Officer | Senior VP, Chief Pharma Dev. | 16 | 2021–2025 | |
| 667, L.P. | Director | 14 | 2023–2026 | ||
| Baker Bros. Advisors (GP) LLC | Director | 14 | 2023–2026 | ||
| BAKER BROS. ADVISORS LP | Director | 15 | 2023–2026 | ||
| Baker Brothers Life Sciences LP | Director | 14 | 2023–2026 | ||
| BAKER FELIX | Director | 14 | 2023–2026 | ||
| BAKER JULIAN | Director | 14 | 2023–2026 | ||
| Cheong Raymond | Director | 1 | 2023 | ||
| Sibold William John | Director,Officer | President and CEO | 14 | 2023–2026 | |
| Huntsman Carole | Officer | Chief Commercial Officer | 10 | 2023–2026 | |
| Dier Mardi | Officer | EVP and CFO; SVP and CFO | 7 | 2024–2026 | |
| Kelley Shannon T | Officer | General Counsel | 9 | 2024–2026 | |
| FOUSE JACQUALYN A | Director | 4 | 2025–2026 | ||
| Soergel David | Officer | Chief Medical Officer | 5 | 2025–2026 | |
| Brennan Daniel J. | Director | 3 | 2025–2026 | ||
| Thakkar Rita | Officer | Chief Accounting Officer | 2 | 2026 | |
| REED JOHN C | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2017-07-05 | MADRIGAL PHARMACEUTICALS, INC. | Pharmaceuticals | $35,000,018 | $35,000,018 | 5 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Madrigal Pharmaceuticals, Inc. | PA | State business registries | name and state |
| Business registration | Madrigal Pharmaceuticals, Inc. | PA | State business registries | name and state |
| Business registration | Madrigal Pharmaceuticals, Inc. | PA | State business registries | name and state |
| Business registration | MADRIGAL PHARMACEUTICALS, INC | PA | State business registries | name and state |
| Business registration | MADRIGAL PHARMACEUTICALS, INC | PA | State business registries | name and state |
| Business registration | MADRIGAL PHARMACEUTICALS, INC | PA | State business registries | name and state |
| Business registration | MADRIGAL PHARMACEUTICALS, INC | PA | State business registries | name and state |
| Business registration | MADRIGAL PHARMACEUTICALS, INC. | PA | State business registries | name and state |
| Plan sponsor | MADRIGAL PHARMACEUTICALS, INC. | PA | Form 5500 (employee benefit plans) | name and state |
| Federal award recipient | MADRIGAL PHARMACEUTICALS, INC | PA | Federal spending (USAspending) | name and state |
| Form D issuer | Madrigal Pharmaceuticals, Inc. | PA | Form D private offerings | name and state |
| Form D issuer | MADRIGAL PHARMACEUTICALS, INC. | PA | Form D private offerings | CIK (EXACT) |
| Lobbying client | MADRIGAL PHARMACEUTICALS | PA | Federal lobbying (LDA) | name and state |
| Lobbying client | MADRIGAL PHARMACEUTICALS, INC. | PA | Federal lobbying (LDA) | name and state |
| Lobbying client | MADRIGAL PHARMACEUTICALS, INC. | PA | Federal lobbying (LDA) | name and state |
| Lobbying client | MADRIGAL PHARMACEUTICALS, INC. | PA | Federal lobbying (LDA) | name and state |
| Lobbying client | MADRIGAL PHARMACEUTICALS, INC. | PA | Federal lobbying (LDA) | name and state |
| Lobbying registrant | MADRIGAL PHARMACEUTICALS, INC. | PA | Federal lobbying (LDA) | name and state |
| Paying company | Madrigal Pharmaceuticals | PA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Madrigal Pharmaceuticals, Inc. | PA | Patents (USPTO) | name and state |
| SEC filer | MADRIGAL PHARMACEUTICALS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Madrigal Pharmaceuticals, Inc. | PA | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, PA first:
- COLLAGENEX PHARMACEUTICALS INC PA
- ORAPHARMA INC PA
- VICURON PHARMACEUTICALS INC PA
- INOVIO PHARMACEUTICALS, INC. PA
- ADOLOR CORP PA
- PROTARGA INC PA
- Traws Pharma, Inc. PA
- Vitae Pharmaceuticals, Inc PA
- PhaseBio Pharmaceuticals Inc PA
- NeuBase Therapeutics, Inc. PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health